Teleflex Investor Presentation

Achieve Earnings and Margin Expansion 10 10 Portfolio Mix High Growth portfolio will continue to drive margin expansion. UroLift 2, MANTA, hemostatic products, intraosseous, PICCs, and bariatric stapling Restructuring Activities Expect to deliver $45-$51M in pre-tax savings for 2023-2025 through previously announced restructuring programs Distributor to Direct Conversions Execute on our acquisition strategy, and reload on our opportunities to convert to direct sales Teleflex®

View entire presentation